文献速递白血病

适合停用酪氨酸激酶抑制剂的慢性期慢性髓性白血病患者疾病进展风险:TFR-PRO 研究最终分析

Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study.
PubMed 文献 · Am J Hematol · 2023-08-30

TFR-PRO 为回顾前瞻性队列研究,纳入 870 例符合停药条件的慢性期慢性髓性白血病患者,分为停药队列 505 例与参考队列 365 例。中位随访 5.5 年、共 5188.2 人年,停药队列无进展事件;总体进展时间调整率为 0.019/100 人年(95%CI [0.003-0.138]),停药队列为 0.0(95%CI [0-0.163]),参考队列为 0.030(95%CI [0.004-0.215]),差异无统计学意义。

要点

  • 停药队列 505 例中无进展至加速期/急变期事件,总体进展时间调整率为 0.019/100 人年。
  • 停药后分子学复发(丧失主要分子学反应)172/505(34.1%),参考队列 64/365(17.5%),p < .0001。
  • 作者认为符合停药条件者疾病进展罕见且与停药无关,对停药进展风险的担忧应予消除。

核心结论

  • 符合停药条件的慢性期慢性髓性白血病患者疾病进展罕见,且与停药无关,对尝试停药者疾病进展风险的担忧应予消除。

研究设计与样本

  • TFR-PRO 为回顾前瞻性队列研究,870 例符合停药条件的慢性期慢性髓性白血病患者构成停药队列(505 例)与参考队列(365 例)。
  • 主要终点为与停药相关进展的时间调整率,次要终点包括分子学复发(丧失主要分子学反应)的时间调整率。

主要发现

  • 中位随访 5.5 年、共 5188.2 人年,停药队列无进展事件;1 例进展事件发生于停药结束后 55 个月,当时该患者计入参考队列。
  • 进展时间调整率总体为 0.019/100 人年(95%CI [0.003-0.138]),停药队列为 0.0(95%CI [0-0.163]),参考队列为 0.030(95%CI [0.004-0.215]),差异无统计学意义。
  • 停药后分子学复发 172/505(34.1%),参考队列 64/365(17.5%),p < .0001。
  • 停药患者在一线、二线或三线治疗中观察到的比率相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Disease progression to accelerated/blast phase (AP/BP) in patients with chronic phase chronic myeloid leukemia (CP-CML) after treatment discontinuation (TD) has never been systematically reported in clinical trials. However, recent reports of several such cases has raised concern. To estimate the risk of AP/BP among TD-eligible patients, we conducted TFR-PRO, a cohort retro-prospective study: 870 CP-CML patients eligible for TD formed a discontinuation cohort (505 patients) and a reference one (365 patients). The primary objective was the time adjusted rate (TAR) of progression in relation to TD. Secondary endpoints included the TAR of molecular relapse, that is, loss of major molecular response (MMR). With a median follow up of 5.5 years and 5188.2 person-years available, no events occurred in the TD cohort. One event of progression was registered 55 months after the end of TD, when the patient was contributing to the reference cohort. The TAR of progression was 0.019/100 person-years (95% CI [0.003-0.138]) in the overall group; 0.0 (95% CI [0-0.163]) in the discontinuation cohort; and 0.030 (95% CI [0.004-0.215]) in the reference cohort. These differences are not statistically significant. Molecular relapses occurred in 172/505 (34.1%) patients after TD, and in 64/365 (17.5%) patients in the reference cohort, p < .0001. Similar rates were observed in TD patients in first, second or third line of treatment. CML progression in patients eligible for TD is rare and not related to TD. Fears about the risk of disease progression among patients attempting TD should be dissipated.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Zambrotta GPM, Nicolini FE, Assouline S, et al. Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study. Am J Hematol. 2023. PMID: 37647134. doi:10.1002/ajh.27073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。